Literature DB >> 33963876

Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset.

Cynthia Kwan1, Stephen G Nuara2, Jim C Gourdon2, Philippe Huot3,4,5.   

Abstract

Parkinson's disease (PD) psychosis afflicts over half of patients and poses a significant burden on quality of life. The aetiology of PD psychosis is multifactorial and likely arises from the complex interaction between dopamine replacement therapy and disease state. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned common marmoset is a validated model to predict the efficacy of therapeutic compounds for treatment-related complications, including PD psychosis. In this model, psychosis-like behaviours (PLBs) encompass stereotypies that are idiosyncratic in nature and reproducible with each L-3,4-dihydroxyphenylanaline (L-DOPA) administration. In the present study, we sought to expand upon the existing repertoire of PLBs through the characterisation of novel stereotypical behaviours that appear dependent on the environment. We then discuss our findings in the context of clinical reports on stereotypical behaviours termed "punding" in subjects with PD, which consists of stereotypical repetitive and senseless behaviours. The poor understanding of the pathophysiology governing punding and consequent lack of effective therapies stand to benefit from enhanced characterisation of these stereotypical behaviours in a validated pre-clinical model. We hope that further characterisation of PLBs in the MPTP-lesioned marmoset will be helpful in the evaluation of interventions that seek to alleviate PD psychosis symptoms.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  L-DOPA; MPTP-lesioned marmoset; Parkinson’s disease; Psychosis; Punding

Mesh:

Substances:

Year:  2021        PMID: 33963876     DOI: 10.1007/s00210-021-02090-6

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  56 in total

1.  Punding and computer addiction in Parkinson's disease.

Authors:  Alfonso Fasano; Antonio E Elia; Francesco Soleti; Arianna Guidubaldi; Anna Rita Bentivoglio
Journal:  Mov Disord       Date:  2006-08       Impact factor: 10.338

2.  Management of punding in Parkinson's disease: an open-label prospective study.

Authors:  A Fasano; L Ricciardi; M Pettorruso; A R Bentivoglio
Journal:  J Neurol       Date:  2010-11-12       Impact factor: 4.849

3.  Is punding a stereotypy?

Authors:  Alfonso Fasano; Andrew H Evans
Journal:  Mov Disord       Date:  2012-12-12       Impact factor: 10.338

Review 4.  Insights into pathophysiology of punding reveal possible treatment strategies.

Authors:  A Fasano; I Petrovic
Journal:  Mol Psychiatry       Date:  2010-06       Impact factor: 15.992

5.  Aromatic amino acids and modification of parkinsonism.

Authors:  G C Cotzias; M H Van Woert; L M Schiffer
Journal:  N Engl J Med       Date:  1967-02-16       Impact factor: 91.245

6.  Behavioral effects of levodopa.

Authors:  Isabelle Beaulieu-Boire; Anthony E Lang
Journal:  Mov Disord       Date:  2014-12-09       Impact factor: 10.338

7.  Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome.

Authors:  Andrew H Evans; Regina Katzenschlager; Dominic Paviour; John D O'Sullivan; Silke Appel; Andrew D Lawrence; Andrew J Lees
Journal:  Mov Disord       Date:  2004-04       Impact factor: 10.338

8.  Cocaine-induced psychosis.

Authors:  K T Brady; R B Lydiard; R Malcolm; J C Ballenger
Journal:  J Clin Psychiatry       Date:  1991-12       Impact factor: 4.384

9.  Cocaine addiction: from habits to stereotypical-repetitive behaviors and punding.

Authors:  Alfonso Fasano; Andrea Barra; Paola Nicosia; Federica Rinaldi; Pietro Bria; Anna Rita Bentivoglio; Federico Tonioni
Journal:  Drug Alcohol Depend       Date:  2008-04-18       Impact factor: 4.492

Review 10.  Epidemiology of psychosis in Parkinson's disease.

Authors:  Gilles Fénelon; Guido Alves
Journal:  J Neurol Sci       Date:  2009-09-08       Impact factor: 3.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.